Cho C S, Knechtle S J, Heisey D M, Hermina M, Armbrust M, D'Alessandro A M, Musat A I, Kalayoglu M
Division of Transplantation, Department of Surgery, University of Wisconsin Hospital and Clinics, Madison, Wis. 53792, USA.
J Gastrointest Surg. 2001 Nov-Dec;5(6):594-601; discussion 601-2. doi: 10.1016/s1091-255x(01)80101-3.
The use of orthotopic liver transplantation (OLTX) for the treatment of hepatocellular carcinoma (HCC) has generally become restricted to carefully selected cases of small oligocentric tumors. However, it is not uncommon to find previously undetected HCC within recipient cirrhotic livers at the time of hepatectomy. The impact of unsuspected HCC on patient outcomes remains unclear. A retrospective analysis of our institutional experience with adult primary OLTX was performed comparing recipients with incidental HCC (group 1), recipients with known or suspected HCC (group 2), and recipients confirmed by pathologic examination to be tumor free (group 3). Between 1984 and 2000, 27 patients in group 1, 12 patients in group 2, and 612 patients in group 3 underwent primary OLTX. Tumors were smaller (P = 0.0172) in group 1 than in group 2; however, the number of tumors and the histologic findings were similar in the groups. Incidence of bilobar involvement, vascular invasion, portal vein tumor thrombus, lymphatic involvement, and distant metastasis at the time of OLTX did not differ significantly between these groups. Four-year patient survival appeared to be lower in group 1 (70.0%) than in group 3 (79.0%) (P = 0.0546); 4-year patient survival was significantly worse in group 2 (31.0%) compared to group 3 (P = 0.0106). Thus, in our experience, incidentally diagnosed cases of HCC possess many of the same features of malignancy as preoperatively diagnosed HCC. Indeed, patient survival after OLTX appears to be adversely affected by the presence of incidental HCC.
原位肝移植(OLTX)用于治疗肝细胞癌(HCC),一般已局限于精心挑选的小的多中心肿瘤病例。然而,在肝切除时,在受体肝硬化肝脏中发现先前未被检测到的HCC并不罕见。未被怀疑的HCC对患者预后的影响仍不清楚。我们对成人原发性OLTX的机构经验进行了回顾性分析,比较了伴有偶然发现的HCC的受体(第1组)、已知或疑似HCC的受体(第2组)以及经病理检查证实无肿瘤的受体(第3组)。1984年至2000年期间,第1组有27例患者、第2组有12例患者、第3组有612例患者接受了原发性OLTX。第1组的肿瘤比第2组小(P = 0.0172);然而,各组的肿瘤数量和组织学表现相似。这些组之间在OLTX时双叶受累、血管侵犯、门静脉肿瘤血栓、淋巴受累和远处转移的发生率没有显著差异。第1组的4年患者生存率(70.0%)似乎低于第3组(79.0%)(P = 0.0546);与第3组相比,第2组的4年患者生存率(31.0%)明显更差(P = 0.0106)。因此,根据我们的经验,偶然诊断的HCC病例具有许多与术前诊断的HCC相同的恶性特征。事实上,OLTX后患者的生存似乎受到偶然发现的HCC的不利影响。